title: Partial response of angiosarcoma of the scalp to sorafenib: association with decreased expression of vascular endothelial growth factors and their receptors.
abstract: The prognosis of angiosarcoma remains very poor, even with combined, multimodal therapy. We report a case with partial response of angiosarcoma of the scalp to sorafenib, which is a new oral, molecular, targeted, multiple-kinase inhibitor. In addition, we confirmed, using immunohistochemistry, that sorafenib suppressed the expression of vascular endothelial growth factors and their receptors on the angiosarcoma tumour cells, and decreased cell numbers by inhibiting cellular proliferation.
authors.affiliation: Department of Dermatology, Osaka City University Graduate School of Medicine, Osaka, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Tamiya
authors.forename: R
authors.initials: R
authors.lastname: Kamo
authors.forename: A
authors.initials: A
authors.lastname: Kumei
authors.forename: S
authors.initials: S
authors.lastname: Yanagihara
authors.forename: M
authors.initials: M
authors.lastname: Ishii
authors.forename: H
authors.initials: H
authors.lastname: Kobayashi
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D006394:Hemangiosarcoma / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D008297:Male; D008875:Middle Aged; D009536:Niacinamide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010671:Phenylurea Compounds / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D040262:Receptors, Vascular Endothelial Growth Factor / Q000378:metabolism; D012535:Scalp; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D000077157:Sorafenib; D016896:Treatment Outcome; D042442:Vascular Endothelial Growth Factors / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D042442:Vascular Endothelial Growth Factors; D009536:Niacinamide; D000077157:Sorafenib; D040262:Receptors, Vascular Endothelial Growth Factor